Radiation therapy in endometrial cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 3, 2001, Pages 417-432

  Koh, Wui Jin ^a   Tran, Audrey B ^a   Douglas, James G ^a   Stelzer, Keith J ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Brachytherapy; Endometrial cancer; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; ENDOMETRIUM CANCER; HIGH RISK PATIENT; HUMAN; PATHOLOGY; PELVIS TUMOR; PHILOSOPHY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK MANAGEMENT; TEAMWORK; TREATMENT OUTCOME;

EID: 0034929453     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0186     Document Type: Article

References (57)

1. The vanishing role of preoperative radiation therapy for stage I endometrial carcinoma
2. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study
3. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study
4. Complete surgical staging of early endometrial adenocarcinoma: Optimizing patient outcomes
5. Complete surgical staging in endometrial cancer provides prognostic information only
6. Surgical staging of endometrial cancer: Does the patient benefit?
7. Surgical staging of endometrial cancer: Evolution, evaluation, and responsible challenge - A personal perspective
8. Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling
9. Stage I corpus cancer: Is teletherapy necessary?
10. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma
11. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage - A Gynecologic Oncology Group Study
12. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: Implications for therapy
13. Tailoring radiation to the extent of disease for uterine-confined endometrial cancer
14. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma
15. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: Comparison of clinicopathologic features and survival
16. Tumor size in endometrial cancer
17. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy
18. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma
19. Endometrial carcinoma - Relative effectiveness of adjuvant irradiation vs therapy reserved for relapse
20. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium
21. Detection and patterns of treatment failure in 300 consecutive cases of 'early' endometrial cancer after primary surgery
22. Surgery without radiotherapy for primary treatment of endometrial cancer
23. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: Multicentre randomised trial
24. A phase III randomized study of surgery vs surgery plus adjunctive radiation therapy in intermediate-risk endometrial adenocarcinoma (GOG No. 99)
25. Benefit of external irradiation in pathologic stage I endometrial carcinoma: A prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors
26. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer
27. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma
28. The role of adjuvant radiotherapy in carcinoma of the endometrium - Results in 550 patients with pathologic stage I disease
29. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?
30. Benefit of adjuvant radiotherapy in surgically staged stage I-II endometrial carcinoma
31. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial
32. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer
33. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: Patterns of relapse and side effects following low-dose therapy
34. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer
35. Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer
36. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma
37. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists
38. NCCN practice guidelines for endometrial carcinoma
39. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis
40. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence
41. Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases
42. Prognostic factors in surgical stage III and IV carcinoma of the endometrium
43. Peritoneal cytology in endometrial cancer: A review
44. The prognostic significance of peritoneal cytology for stage I endometrial cancer
45. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease
46. Endometrial cancer with para-aortic adenopathy: Patterns of failure and opportunities for cure
47. Radiation therapy of periaortic node metastases in cancer of the uterine cervix and endometrium
48. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation
49. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma
50. Pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients following adjuvant chemotherapy alone: Implications for locoregional radiation therapy
51. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer
52. Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients
53. Treatment of endometrial carcinoma with radiation therapy alone
54. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium
55. Uterine papillary serous carcinoma: Patterns of metastatic spread
56. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy
57. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients